A pentasaccharide derivative in which N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.


A member of the class of azabicycloalkanes that is 1-azabicyclo[3.2.0]heptan-7-one substituted at positions 3 and 6 by (2-aminoethyl)thio and methyl groups respectively.


Laryngeal Cancer cM0 TNM Finding v8

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Laryngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)


A beta-D-glucoside compound having a (pentanoyl)-phloroglucinyl moiety at the anomeric position. Isolated from the whole plant of Indigofera heterantha, it exhibits lipoxygenase inhibitory activity.


name: epilepsy, juvenile myoclonic, susceptibility to, 9

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing


An omega-hydroxy fatty acid ascaroside that is oscr#18 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.


name: Grade 3 Peripheral Motor Neuropathy, CTCAE

description: Severe symptoms; limiting self care ADL


Grade 1 Testicular Pain, CTCAE

description: Mild pain


Grade 3 Bladder Spasm, CTCAE

description: Hospitalization indicated


GDP-beta-L-fucose

A GDP-L-fucose in which the anomeric oxygen is on the same side of the fucose ring as the methyl substituent.


name: ammonium magnesium phosphate hexahydrate

description: A hydrate that is the hexahydrate form of ammonium magnesium phosphate. It is a constituent of urinary calculi.


fluorapatite

A phosphate mineral with the formula Ca5(PO4)3F.


chlorapatite

A phosphate mineral with the formula Ca5(PO4)3Cl.


apatite

A phosphate mineral with the general formula Ca5(PO4)3X where X = OH, F or Cl.


Grade 3 Venous Injury, CTCAE

description: Severe symptoms; limiting self care ADL; repair or revision indicated


Prostate Cancer cT3a TNM Finding v8

description: Prostate cancer with extraprostatic extension (unilateral or bilateral). (from AJCC 8th Ed.)


name: Prostate Cancer Clinical Primary Tumor TNM Finding v8

description: A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.


Prostate Cancer cT2 TNM Finding v8

description: Prostate cancer in which the tumor is palpable and confined within the prostate. (from AJCC 8th Ed.)


Prostate Cancer cT1a TNM Finding v8

description: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. (from AJCC 8th Ed.)


Prostate Cancer cTX TNM Finding v8

description: Prostate cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)


Prostate Cancer cT4 TNM Finding v8

description: Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 8th Ed.)


Prostate Cancer cT2c TNM Finding v8

description: Prostate cancer in which the tumor involves both sides. (from AJCC 8th Ed.)


Prostate Cancer cT3b TNM Finding v8

description: Prostate cancer in which the tumor invades seminal vesicle(s). (from AJCC 8th Ed.)


Prostate Cancer cT1b TNM Finding v8

description: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. (from AJCC 8th Ed.)


Prostate Cancer cT3 TNM Finding v8

description: Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. (from AJCC 8th Ed.)


Prostate Cancer cT0 TNM Finding v8

description: Prostate cancer with no evidence of primary tumor. (from AJCC 8th Ed.)


Prostate Cancer cT1c TNM Finding v8

description: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. (from AJCC 8th Ed.)


Prostate Cancer cT1 TNM Finding v8

description: Prostate cancer with clinically inapparent tumor that is not palpable. (from AJCC 8th Ed.)


Prostate Cancer cT2a TNM Finding v8

description: Prostate cancer in which the tumor involves one-half of one side or less. (from AJCC 8th Ed.)


Prostate Cancer cT2b TNM Finding v8

description: Prostate cancer in which the tumor involves more than one-half of one side but not both sides. (from AJCC 8th Ed.)


name: Other Specified Diabetes Mellitus with Mild Nonproliferative Diabetic Retinopathy with Macular Edema, Right Eye

description: Evidence of other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema in the right eye not specified elsewhere.


name: Malignant Neoplasm of Lower-Inner Quadrant of Right Male Breast

description: Evidence of a malignant neoplasm of the lower-inner quadrant of right male breast.


N2 TNM Finding

description: A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes. The definition of N2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4-9 axillary lymph nodes; for cutaneous melanoma it refers to metastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4 or more regional lymph nodes; and for bladder cancer it refers to metastases in multiple regional lymph nodes in the true pelvis.


N2a TNM Finding

description: A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2a TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0 mm); for cutaneous melanoma it refers to micrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in 4-6 regional lymph nodes.


N2b TNM Finding

description: A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2b TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to metastases only in clinically detected ipsilateral internal mammary nodes and in the absence of clinically evident level I, II axillary lymph node metastases; for cutaneous melanoma it refers to macrometastases in 2-3 regional lymph nodes; for colorectal cancer it refers to metastases in seven or more regional lymph nodes.


N2c TNM Finding

description: A general term that refers to a TNM finding of cancer metastases in several regional lymph nodes.  The definition of N2c TNM finding depends on the specific type of cancer that it refers to; for example, for cutaneous melanoma it refers to intralymphatic metastases (in transit or satellite metastases) without metastatic nodes; for lip and oral cavity cancer it refers to metastases in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension.


A perchlorometallate anion having six chlorines and rhodium(IV) as the metal component.


name: Malignant Neoplasm of Right Main Bronchus

description: Evidence of a malignant neoplasm of the right main bronchus.


Abnormal Mammogram

description: A radiologic finding indicating the presence of abnormalities in the breast parenchyma identified in a mammogram performed for screening or diagnostic purposes.  These abnormalities include calcifications, breast tissue distortion, presence of areas of density, and presence of benign or malignant tumors.


Grade 2 Delayed Orgasm, CTCAE

description: Delay in achieving orgasm adversely affecting relationship


Cervical Squamotransitional Carcinoma

description: A human papillomavirus-related cervical squamous cell carcinoma characterized by the presence of papillary structures with fibrovascular cores. It is covered with multiple layers of atypical cells that resemble cervical intraepithelial neoplasia 3.


name: Grade 2 Hearing Patients with or without Baseline Audiogram and Enrolled in a Monitoring Program, CTCAE


name: Hearing Patients with or without Baseline Audiogram and Enrolled in a Monitoring Program, CTCAE


name: Grade 3 Hearing Patients with or without Baseline Audiogram and Enrolled in a Monitoring Program, CTCAE


name: Grade 4 Hearing Patients with or without Baseline Audiogram and Enrolled in a Monitoring Program, CTCAE


name: Grade 1 Hearing Patients with or without Baseline Audiogram and Enrolled in a Monitoring Program, CTCAE


2-aminobut-2-enoic acid zwitterion

An amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of 2-aminobut-2-enoic acid; major species at pH 7.3.


name: Grade 3 Salivary Duct Inflammation, CTCAE

description: Acute salivary gland necrosis; severe secretion-induced symptoms (e.g., thick saliva/oral secretions or gagging); tube feeding or TPN indicated; limiting self care ADL


An N-acyl-1-O-beta-D-glucosyl-4-hydroxy-15-methylhexadecasphinganine in which the acyl group has 17 carbons and 0 double bonds and is 2-hydroxylated.


ISOXATHION

An organic thiophosphate  that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group is replaced by a 5-phenyl-1,2-oxazol-3-yl group.


N(6)-acyl-L-lysine zwitterion

Zwitterionic form of an N(6)-acyl-L-lysine.


Zwitterionic form of N(6)-[(indol-3-yl)acetyl]-L-lysine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3.


Transformed migraine

description: Episodes of migraine occurring on 15 or more days per month, for more than three months.


A dihydroxydocosahexaenoic acid that is (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 14S- and 22-positions.


name: 1-[2-[[(2-chloroanilino)-oxomethyl]amino]-2-methyl-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester


name: Grade 4 Cranial Nerve III Neuropathy, CTCAE


name: E. coli strain 0111 B4 lipopolysaccharide

description: A lipopolysaccharide that is produced by E. coli strain 0111 B4.


alvaradoin L

A C-glycosyl compound that is 1,8-dihydroxy-3-methylanthracen-9(10H)-one substituted by a 2-O-senecioyl-alpha-lyxopyranosyl moiety at position 10 via a C-glycosidic linkage (the 10S stereoisomer). It is isolated from the leaves of Alvaradoa haitiensis and exhibits cytotoxicity against human oral epidermoid carcinoma.


L-isoleucine 2-naphthylamide

An L-isoleucine derivative that is the amide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of 2-naphthylamine.


sodium bromate

An inorganic sodium salt having bromate as the counterion.


description: A reactive proliferation of the conjunctival epithelium associated with the presence of prominent glandular elements.


Spinal arthritis deformans

description: Degenerative arthritis of the spinal column.


name: Amyotrophic Lateral Sclerosis 14, With or Without Frontotemporal Dementia

description: A form of amyotrophic lateral sclerosis caused by heterozygous mutation(s) in the VCP gene, encoding transitional endoplasmic reticulum ATPase.


Spastic Paraplegia 30

description: An autosomal recessive subtype of hereditary spastic paraplegia caused by mutation(s) in the KIF1A gene, encoding kinesin-like protein KIF1A.


Presenile dementia

description: The presence of dementia in an individual younger than age sixty five.


Amyotrophic Lateral Sclerosis 25

description: An autosomal dominant form of amyotrophic lateral sclerosis caused by mutation(s) in the KIF5A gene, encoding kinesin heavy chain isoform 5A.


Spastic Paraplegia 76

description: An autosomal recessive subtype of hereditary spastic paraplegia caused by mutation(s) in the CAPN1 gene, encoding calpain-1 catalytic subunit.


name: Neurodegeneration with Brain Iron Accumulation 2A

description: An autosomal recessive condition caused by mutation(s) in the PLA2G6 gene, encoding 85/88 kDa calcium-independent phospholipase A2. It is characterized by axonal swelling and spheroid bodies in the central nervous system. The onset is typically in the first two years of life.


Grade 3 Gynecomastia, CTCAE

description: Severe symptoms; elective operative intervention indicated


Grade 2 Gynecomastia, CTCAE

description: Symptomatic (e.g., pain or psychosocial impact)


palmitoleyl alcohol

A member of the class of hexadecen-1-ols that is hexadecanol containing a double bond located at position 9 (the Z-geoisomer).


An optically active 5-oxo-1,2-campholide having (-)-(1R,5R)-configuration.


LUCENSIMYCIN E

An organic heterotetracyclic compound isolated from the bacterial strain Streptomyces lucensis MA7349 and has been shown to exhibit antibacterial activity.


A bridged compound that is 1,2-campholide substituted at position 5 by an oxo group.


An optically active 5-oxo-1,2-campholide having (+)-(1S,5S)-configuration.


A diarylheptanoid that is (6E)-6-hepten-3-ol substituted by a 3,4-dihydroxyphenyl group at position 1 and a phenyl group at position 7 (the 3R- stereoisomer). It has been isolated from the rhizomes of Curcuma kwangsiensis.


name: Grade 1 Ligament Intra-Operative Injury, CTCAE


PRENISTEINE

A prenylcysteine where the prenyl moiety is attached to the side-chain sulfur atom of L-cysteine.


name: Unresectable Pancreatic Neuroendocrine Tumor G3

description: Pancreatic neuroendocrine tumor G3 that is not amenable to surgical resection.


A member of the class of delta-lactams that is 2-piperidinone in which the amide hydrogen is replaced by a 4-bromobutyl group.


Cutaneous Melanoma pNX TNM Finding v7

description: Cutaneous melanoma in which the regional lymph nodes cannot be assessed (e.g., previously removed for another reason).  (from AJCC 7th Ed.)


name: Nasal Cavity and Ethmoid Sinus Cancer Pathologic Distant Metastasis TNM Finding v6

description: A pathologic finding about one or more characteristics of nasal cavity and ethmoid sinus cancer, following the rules of the TNM AJCC v6 classification system as they pertain to distant metastases.


name: Nasal Cavity and Ethmoid Sinus Cancer pM0 TNM Finding

description: Nasal cavity and ethmoid sinus cancer with no distant metastasis. (from AJCC 6th Ed.)


name: Nasal Cavity and Ethmoid Sinus Cancer pM1 TNM Finding v6 and v7

description: Nasal cavity and ethmoid sinus cancer with distant metastasis. (from AJCC 6th and 7th Eds.)


name: Nasal Cavity and Ethmoid Sinus Cancer pMX TNM Finding v6

description: Nasal cavity and ethmoid sinus cancer in which distant metastasis cannot be assessed. (from AJCC 6th Ed.)


An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.


name: Type 2 Diabetes Mellitus with Mild Nonproliferative Diabetic Retinopathy without Macular Edema

description: Evidence of type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema.


plakortolide S

An organic heterobicyclic compound that is a cyclic peroxy compound isolated from the Australian marine sponge Plakinastrella clathrata.


name: Malignant Neoplasm of Unspecified Part of Left Adrenal Gland

description: Evidence of a malignant neoplasm of an unspecified part of left adrenal gland.


N-ethyl-L-asparagine

An optically active form of N-ethylasparagine having L-configuration.


N-ethylasparagine

A dicarboxylic acid monoamide that is asparagine in which one of the hydrogens attached to the nitrogen of the alpha-amino group is replaced by an ethyl group.


name: Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0 TNM Finding v8

description: No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)


name: Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0a TNM Finding v8

description: One or more cytologically or histologically confirmed benign lymph nodes. (from AJCC 8th Ed.)


name: Gastric Neuroendocrine Tumor pT0 TNM Finding v8

description: Gastric neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)


Grade 3 Skin Atrophy, CTCAE

description: Covering >30% BSA; associated with ulceration


name: 4-[2-[[1-[(2-methylphenyl)methyl]-3-indolyl]sulfonyl]-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester


hydrocortisone phosphate

A steroid phosphate that is the 21-O-phospho derivative of cortisol.


estramustine phosphate

A steroid phosphate which is the 17-O-phospho derivative of estramustine.


betamethasone phosphate

A steroid phosphate that is the 21-O-phospho derivative of betamethasone.


A hydroxyoctadecatrienoic acid that consists of 6Z,9Z,11E-octadecatrienoic acid having the hydroxy group located at position 13.


name: Perihilar Bile Duct Cancer TNM Finding v7

description: A finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v7 classification system.  Sarcomas and carcinoid tumors are not included. (from AJCC 7th Ed.)


name: Perihilar Bile Duct Cancer cM0 TNM Finding v7

description: Perihilar bile duct cancer without evidence of distant metastasis. (from AJCC 7th Ed.)


name: Perihilar Bile Duct Cancer Clinical TNM Finding v7

description: A clinical finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v7 classification system.  The clinical evaluation usually depends on the results of duplex ultrasound, computed tomography, and magnetic resonance cholangiopancreatography (MRCP).  The biliary extent of disease is assessed with percutaneous transhepatic cholangiography or MRCP.  Clinical staging also may be based on findings from surgical exploration when the main tumor mass is not resected.  (from AJCC 7th Ed.)


name: Perihilar Bile Duct Cancer Clinical Distant Metastasis TNM Finding v7

description: A clinical finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.


name: Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11

description: An acute myeloid leukemia with inv(16)(p13.1q22); CBFB-MYH11 occurring in adults.


An acyl tetraketide pyran-2-one that is 4-hydroxy-2H-pyran-2-one in which the hydrogen at position 6 is replaced by a 13-methyl-2-oxotetradecyl group.


2-amino-4-oxopentanoic acid zwitterion

Zwitterionic form of 2-amino-4-oxopentanoic acid having an anionic carboxy group and a protonated amino group.


A 2-amino-4-oxopentanoic acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of (R)-2-amino-4-oxopentanoic acid; major microspecies at pH 7.3.


name: Grade 5 Postoperative Thoracic Procedure Complication, CTCAE

description: Death


name: 2-[4-(3-chlorophenyl)-1-piperazinyl]-3-pyridinecarboxylic acid propan-2-yl ester


A glycosylglycerol that is  1-O-(D-glucosyl)glycerol in which the secondary hydroxy group of the glycerol moiety has been converted into the corresponding L-fucopyranoside.


Grade 2 Arthritis, CTCAE

description: Moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL


name: Musculoskeletal and Connective Tissue Disorders, CTCAE


name: Grade 2 Neck Soft Tissue Necrosis, CTCAE

description: Local wound care; medical intervention indicated (e.g., dressings or topical medications)


Muscle Cramp, CTCAE

description: A disorder characterized by marked cramping sensation originating from a muscle or group of muscles.


name: Grade 3 Muscle Weakness Lower Limb, CTCAE

description: Limiting self care ADL


Grade 3 Arthralgia, CTCAE

description: Severe pain; limiting self care ADL


Arthritis, CTCAE

description: A disorder characterized by inflammation involving a joint.


Grade 1 Avascular Necrosis, CTCAE

description: Asymptomatic; clinical or diagnostic observations only; intervention not indicated


Grade 3 Unequal Limb Length, CTCAE

description: Severe length discrepancy >5 cm; limiting self care ADL; operative intervention indicated


Grade 3 Scoliosis, CTCAE

description: >45 degrees; scapular prominence in forward flexion; operative intervention indicated; limiting self care ADL


name: Grade 3 Joint Range of Motion Decreased Cervical Spine, CTCAE

description: Ankylosed/fused over multiple segments with no C-spine rotation


name: Grade 3 Muscle Weakness Upper Limb, CTCAE

description: Limiting self care ADL


name: Grade 3 Soft Tissue Necrosis Upper Limb, CTCAE

description: Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)


Grade 2 Osteonecrosis of Jaw, CTCAE

description: Symptomatic; medical intervention indicated (e.g., topical agents); limiting instrumental ADL


Grade 3 Chest Wall Pain, CTCAE

description: Severe pain; limiting self care ADL


name: Grade 4 Soft Tissue Necrosis Upper Limb, CTCAE

description: Life-threatening consequences; urgent intervention indicated


Joint Effusion, CTCAE 5.0

description: A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.


Joint Range of Motion Decreased, CTCAE

description: A disorder characterized by a decrease in joint flexibility of any joint.


Grade 1 Pain In Extremity, CTCAE

description: Mild pain


Kyphosis, CTCAE

description: A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.


Grade 3 Pain In Extremity, CTCAE

description: Severe pain; limiting self care ADL


name: Grade 2 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE

description: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL


Grade 2 Exostosis, CTCAE

description: Symptomatic; limiting instrumental ADL


Trismus, CTCAE

description: A disorder characterized by lack of ability to open the mouth fully due to a decrease in the range of motion of the muscles of mastication.


Grade 1 Rotator Cuff Injury, CTCAE

description: Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated


Grade 1 Unequal Limb Length, CTCAE

description: Mild length discrepancy <2 cm


Grade 1 Myositis, CTCAE

description: Mild pain


Rotator Cuff Injury, CTCAE

description: A disorder characterized by an injury of the rotator cuff.


name: Grade 1 Musculoskeletal Deformity, CTCAE

description: Cosmetically and functionally insignificant hypoplasia


Myositis, CTCAE 5.0

description: A disorder characterized by inflammation involving the skeletal muscles.


name: Grade 5 Pelvic Soft Tissue Necrosis, CTCAE

description: Death


Exostosis, CTCAE 5.0

description: A disorder characterized by non-neoplastic overgrowth of bone.


Grade 3 Buttock Pain, CTCAE

description: Severe pain; limiting self care ADL


Muscle Weakness Upper Limb, CTCAE

description: A disorder characterized by a reduction in the strength of the upper limb muscles.


Grade 3 Myalgia, CTCAE

description: Severe pain; limiting self care ADL


Grade 3 Osteoporosis, CTCAE

description: Adult: Loss of height >=2 cm; hospitalization indicated; limiting self care ADL; Pediatric: Limiting self care ADL


Grade 1 Myalgia, CTCAE

description: Mild pain


Grade 4 Rhabdomyolysis, CTCAE

description: Life-threatening consequences; dialysis


Grade 2 Unequal Limb Length, CTCAE

description: Moderate length discrepancy 2-5 cm; shoe lift indicated; limiting instrumental ADL


name: Grade 2 Joint Range of Motion Decreased Lumbar Spine, CTCAE

description: Pain with range of motion (ROM) in lumbar spine; requires a reaching aid to pick up a very light object from the floor


Superficial Soft Tissue Fibrosis, CTCAE

description: A disorder characterized by fibrotic degeneration of the superficial soft tissues.


Grade 2 Flank Pain, CTCAE

description: Moderate pain; limiting instrumental ADL


Grade 3 Neck Pain, CTCAE

description: Severe pain; limiting self care ADL


name: Grade 3 Head Soft Tissue Necrosis, CTCAE

description: Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)


name: Joint Range of Motion Decreased Lumbar Spine, CTCAE

description: A disorder characterized by a decrease in flexibility of a lumbar spine joint.


name: Grade 2 Soft Tissue Necrosis Lower Limb, CTCAE

description: Local wound care; medical intervention indicated (e.g., dressings or topical medications)


name: Grade 1 Muscle Weakness Upper Limb, CTCAE

description: Symptomatic; perceived by patient but not evident on physical exam


Grade 3 Bone Pain, CTCAE

description: Severe pain; limiting self care ADL


Osteoporosis, CTCAE 5.0

description: A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.


Grade 1 Flank Pain, CTCAE

description: Mild pain


name: Grade 1 Joint Range of Motion Decreased Lumbar Spine, CTCAE

description: Stiffness; difficulty bending to the floor to pick up a very light object but able to do athletic activity


Grade 5 Rhabdomyolysis, CTCAE

description: Death


name: Grade 3 Pelvic Soft Tissue Necrosis, CTCAE


Grade 1 Scoliosis, CTCAE

description: <20 degrees; clinically undetectable


Grade 1 Neck Pain, CTCAE

description: Mild pain


name: Grade 3 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE

description: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL


Fibrosis Deep Connective Tissue, CTCAE

description: A disorder characterized by fibrotic degeneration of the deep connective tissues.


name: Grade 3 Joint Range of Motion Decreased Lumbar Spine, CTCAE

description: <50% lumbar spine flexion; associated with symptoms of ankylosis or fused over multiple segments with no L-spine flexion (e.g., unable to reach to floor to pick up a very light object)


Grade 1 Chest Wall Pain, CTCAE

description: Mild pain


Grade 4 Osteonecrosis of Jaw, CTCAE

description: Life-threatening consequences; urgent intervention indicated


Grade 3 Osteonecrosis, CTCAE

description: Severe symptoms; limiting self care ADL; elective operative intervention indicated


Lordosis, CTCAE

description: A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.


Grade 2 Myositis, CTCAE

description: Moderate pain associated with weakness; pain limiting instrumental ADL


Grade 2 Scoliosis, CTCAE

description: >20-45 degrees; visible by forward flexion; limiting instrumental ADL


Grade 3 Joint Effusion, CTCAE

description: Severe symptoms; limiting self care ADL; invasive intervention indicated


Grade 3 Arthritis, CTCAE

description: Severe pain associated with signs of inflammation, erythema, or joint swelling; irreversible joint damage; limiting self care ADL


name: Grade 2 Muscle Weakness Upper Limb, CTCAE

description: Symptomatic; evident on physical exam; limiting instrumental ADL


Grade 2 Avascular Necrosis, CTCAE

description: Symptomatic; limiting instrumental ADL


name: Grade 1 Generalized Muscle Weakness, CTCAE


name: Grade 4 Neck Soft Tissue Necrosis, CTCAE


Grade 1 Exostosis, CTCAE

description: Asymptomatic; clinical or diagnostic observations only; intervention not indicated


Grade 1 Buttock Pain, CTCAE

description: Mild pain


name: Grade 2 Pelvic Soft Tissue Necrosis, CTCAE


name: Grade 5 Superficial Soft Tissue Fibrosis, CTCAE

description: Death


name: Grade 1 Joint Range of Motion Decreased, CTCAE

description: <=25% loss of ROM (range of motion); decreased ROM limiting athletic activity


Grade 1 Osteoporosis, CTCAE

description: Adult: Radiologic evidence of osteoporosis or Bone Mineral Density (BMD) t-score -1 to -2.5 (osteopenia); Pediatric: Radiologic evidence of low BMD with z score of <= -2.0 and no history of significant fractures


name: Grade 1 Muscle Weakness Lower Limb, CTCAE

description: Symptomatic; perceived by patient but not evident on physical exam


Grade 1 Growth Suppression, CTCAE

description: Reduction in growth velocity by 10-29% ideally measured over the period of a year


name: Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE


name: Grade 4 Head Soft Tissue Necrosis, CTCAE


name: Grade 4 Superficial Soft Tissue Fibrosis, CTCAE

description: Generalized; associated with signs or symptoms of impaired breathing or feeding


Grade 3 Muscle Cramp, CTCAE

description: Severe pain; limiting self care ADL


Back Pain, CTCAE 5.0

description: A disorder characterized by a sensation of marked discomfort in the back region.


name: Grade 2 Soft Tissue Necrosis Upper Limb, CTCAE

description: Local wound care; medical intervention indicated (e.g., dressings or topical medications)


Grade 5 Chest Wall Necrosis, CTCAE

description: Death


Musculoskeletal Deformity, CTCAE

description: A disorder characterized by a malformation of the musculoskeletal system.


Grade 2 Rhabdomyolysis, CTCAE

description: Non-urgent intervention indicated


name: Grade 2 Joint Range of Motion Decreased, CTCAE

description: >25-50% decrease in ROM; limiting instrumental ADL


Grade 3 Rhabdomyolysis, CTCAE

description: Symptomatic, urgent intervention indicated


Grade 5 Osteonecrosis, CTCAE

description: Death


Buttock Pain, CTCAE 5.0

description: A disorder characterized by a sensation of marked discomfort in the buttocks.


name: Grade 3 Joint Range of Motion Decreased, CTCAE

description: >50% decrease in ROM; limiting self care ADL


Grade 2 Muscle Cramp, CTCAE

description: Moderate pain; limiting instrumental ADL


name: Grade 1 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE

description: Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated


Soft Tissue Necrosis Upper Limb, CTCAE

description: A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.


name: Grade 2 Superficial Soft Tissue Fibrosis, CTCAE

description: Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL


Osteonecrosis of Jaw, CTCAE

description: A disorder characterized by a necrotic process occurring in the bone of the mandible.


Grade 1 Trismus, CTCAE

description: Decreased ROM (range of motion) without impaired eating


Grade 3 Myositis, CTCAE

description: Pain associated with severe weakness; limiting self care ADL


Grade 1 Muscle Cramp, CTCAE

description: Mild pain


Grade 1 Bone Pain, CTCAE

description: Mild pain


Grade 3 Flank Pain, CTCAE

description: Severe pain; limiting self care ADL


name: Grade 4 Pelvic Soft Tissue Necrosis, CTCAE

description: Life-threatening consequences; urgent intervention indicated


Flank Pain, CTCAE

description: A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.


Growth Suppression, CTCAE

description: A disorder characterized by stature that is smaller than normal as expected for age.


name: Grade 5 Fibrosis Deep Connective Tissue, CTCAE

description: Death


Grade 5 Osteonecrosis of Jaw, CTCAE

description: Death


name: Grade 2 Generalized Muscle Weakness, CTCAE

description: Symptomatic; evident on physical exam; limiting instrumental ADL


name: Grade 1 Fibrosis Deep Connective Tissue, CTCAE

description: Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)


Unequal Limb Length, CTCAE

description: A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.


name: Grade 5 Soft Tissue Necrosis Lower Limb, CTCAE

description: Death


Myalgia, CTCAE

description: A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.


Neck Pain, CTCAE 5.0

description: A disorder characterized by a sensation of marked discomfort in the neck area.


Grade 3 Growth Suppression, CTCAE

description: Reduction in growth velocity of >=50% ideally measured over the period of a year


name: Grade 2 Joint Range of Motion Decreased Cervical Spine, CTCAE

description: Rotation <60 degrees to right or left; <60 degrees of flexion


Grade 2 Kyphosis, CTCAE

description: Moderate accentuation; limiting instrumental ADL


name: Grade 3 Soft Tissue Necrosis Lower Limb, CTCAE

description: Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)


Grade 3 Muscle Weakness Trunk, CTCAE

description: Limiting self care ADL


Avascular Necrosis, CTCAE

description: A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.


name: Grade 5 Soft Tissue Necrosis Upper Limb, CTCAE

description: Death


Grade 1 Joint Effusion, CTCAE

description: Asymptomatic; clinical or diagnostic observations only; intervention not indicated


Grade 3 Osteonecrosis of Jaw, CTCAE

description: Severe symptoms; limiting self care ADL; elective operative intervention indicated


name: Grade 3 Abdominal Soft Tissue Necrosis, CTCAE


Grade 2 Back Pain, CTCAE

description: Moderate pain; limiting instrumental ADL


Pelvic Soft Tissue Necrosis, CTCAE

description: A disorder characterized by a necrotic process occurring in the soft tissues of the pelvis.


Pain In Extremity, CTCAE

description: A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.


Grade 5 Avascular Necrosis, CTCAE

description: Death


name: Grade 2 Muscle Weakness Lower Limb, CTCAE


Grade 4 Avascular Necrosis, CTCAE

description: Life-threatening consequences; urgent intervention indicated


name: Grade 5 Abdominal Soft Tissue Necrosis, CTCAE

description: Death


name: Grade 4 Soft Tissue Necrosis Lower Limb, CTCAE


Chest Wall Pain, CTCAE 5.0

description: A disorder characterized by a sensation of marked discomfort in the chest wall.


name: Grade 2 Abdominal Soft Tissue Necrosis, CTCAE

description: Local wound care; medical intervention indicated (e.g., dressings or topical medications)


Grade 3 Rotator Cuff Injury, CTCAE

description: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self care ADL


Muscle Weakness Trunk, CTCAE

description: A disorder characterized by a reduction in the strength of the trunk muscles.


Generalized Muscle Weakness, CTCAE

description: A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.


Grade 3 Back Pain, CTCAE

description: Severe pain; limiting self care ADL


Soft Tissue Necrosis Lower Limb, CTCAE

description: A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.


name: Grade 4 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE


name: Grade 5 Neck Soft Tissue Necrosis, CTCAE

description: Death


Chest Wall Necrosis, CTCAE

description: A disorder characterized by a necrotic process occurring in the soft tissues of the chest wall including breast.


Grade 2 Rotator Cuff Injury, CTCAE

description: Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL


name: Grade 3 Fibrosis Deep Connective Tissue, CTCAE

description: Severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self care ADL


Muscle Weakness Lower Limb, CTCAE

description: A disorder characterized by a reduction in the strength of the lower limb muscles.


Grade 2 Growth Suppression, CTCAE

description: Reduction in growth velocity by 30-49% ideally measured over the period of a year or 0-49% reduction in growth from the baseline growth curve


Abdominal Soft Tissue Necrosis, CTCAE

description: A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.


Grade 1 Rhabdomyolysis, CTCAE

description: Asymptomatic, intervention not indicated; laboratory findings only


Grade 1 Lordosis, CTCAE

description: Asymptomatic; clinical or diagnostic observations only; intervention not indicated


Arthralgia, CTCAE

description: A disorder characterized by a sensation of marked discomfort in a joint.


Grade 2 Osteoporosis, CTCAE

description: Adult: BMD t-score < -2.5; loss of height <2 cm; therapy to improve BMD indicated; limiting instrumental ADL; Pediatric: Low BMD (z-score <= -2.0) and significant fracture history (defined as a long bone fracture of the lower extremity, vertebral compression, 2 or more long bone fractures of the upper extremities); therapy to improve BMD indicated


name: Grade 3 Generalized Muscle Weakness, CTCAE

description: Limiting self care ADL


Grade 3 Avascular Necrosis, CTCAE

description: Severe symptoms; limiting self care ADL; elective operative intervention indicated


name: Grade 4 Fibrosis Deep Connective Tissue, CTCAE

description: Generalized; associated with signs or symptoms of impaired breathing or feeding


Grade 2 Chest Wall Necrosis, CTCAE

description: Local wound care; medical intervention indicated (e.g., dressings or topical medications)


Rhabdomyolysis, CTCAE

description: A disorder characterized by the breakdown of muscle tissue resulting in the release of muscle fiber contents into the bloodstream.


name: Grade 4 Abdominal Soft Tissue Necrosis, CTCAE

description: Life-threatening consequences; urgent intervention indicated


Grade 2 Muscle Weakness Trunk, CTCAE

description: Symptomatic; evident on physical exam; limiting instrumental ADL


Bone Pain, CTCAE 5.0

description: A disorder characterized by a sensation of marked discomfort in the bones.


Scoliosis, CTCAE

description: A disorder characterized by a malformed, lateral curvature of the spine.


Grade 1 Back Pain, CTCAE

description: Mild pain


Grade 3 Lordosis, CTCAE

description: Severe accentuation; operative intervention indicated; limiting self care ADL


name: Joint Range of Motion Decreased Cervical Spine, CTCAE

description: A disorder characterized by a decrease in flexibility of a cervical spine joint.


Grade 2 Osteonecrosis, CTCAE

description: Symptomatic; medical intervention indicated (e.g., analgesics or bisphosphonates); limiting instrumental ADL


Grade 3 Chest Wall Necrosis, CTCAE

description: Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)


Neck Soft Tissue Necrosis, CTCAE

description: A disorder characterized by a necrotic process occurring in the soft tissues of the neck.


Head Soft Tissue Necrosis, CTCAE

description: A disorder characterized by a necrotic process occurring in the soft tissues of the head.


Grade 1 Arthritis, CTCAE

description: Mild pain with inflammation, erythema, or joint swelling


name: Grade 5 Head Soft Tissue Necrosis, CTCAE

description: Death


Grade 2 Lordosis, CTCAE

description: Moderate accentuation; limiting instrumental ADL


name: Grade 1 Joint Range of Motion Decreased Cervical Spine, CTCAE

description: Mild restriction of rotation or flexion between 60-70 degrees


name: Grade 3 Musculoskeletal Deformity, CTCAE

description: Significant deformity, hypoplasia, or asymmetry, unable to be remediated by prosthesis or covered by clothing; limiting self care ADL


name: Grade 1 Superficial Soft Tissue Fibrosis, CTCAE

description: Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)


Grade 1 Arthralgia, CTCAE

description: Mild pain


Grade 2 Joint Effusion, CTCAE

description: Symptomatic; limiting instrumental ADL


Grade 2 Bone Pain, CTCAE

description: Moderate pain; limiting instrumental ADL


name: Grade 5 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE

description: Death


Grade 5 Vaginal Hemorrhage, CTCAE

description: Death


name: Intrahepatic Bile Duct Cancer pN0 TNM Finding v8

description: Intrahepatic bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)


cis-ferulic acid

A ferulic acid consisting of cis-cinnamic acid bearing methoxy and hydroxy substituents at positions 3 and 4 respectively on the phenyl ring.


An amino disaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose and D-galactopyranose residues joined by a (1->3) glycosidic bond.


Anal Cancer pN1 TNM Finding v8

description: Anal cancer with metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. (from AJCC 8th Ed.)


Anal Cancer Pathologic TNM Finding v8

description: A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system.


Anal Cancer pM1 TNM Finding v8

description: Anal cancer with distant metastasis. (from AJCC 8th Ed.)


Anal Cancer pN0 TNM Finding v8

description: Anal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)


Anal Cancer pT2 TNM Finding v8

description: Anal cancer with tumor larger than 2 cm but equal to or smaller than 5 cm. (from AJCC 8th Ed.)


Anal Cancer pTX TNM Finding v8

description: Anal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)


Anal Cancer pTis TNM Finding v8

description: Anal cancer with a finding of high-grade squamous intraepithelial lesion (previously termed carcinoma in situ, Bowen disease, anal intraepithelial neoplasia II-III, high-grade anal intraepithelial neoplasia). (from AJCC 8th Ed.)


Anal Cancer pN1c TNM Finding v8

description: Anal cancer with metastasis in external iliac with any N1a nodes. (from AJCC 8th Ed.)


Anal Cancer pT3 TNM Finding v8

description: Anal cancer with tumor larger than 5 cm. (from AJCC 8th Ed.)


Anal Cancer pNX TNM Finding v8

description: Anal cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)


Anal Cancer pN1b TNM Finding v8

description: Anal cancer with metastasis in external iliac lymph nodes. (from AJCC 8th Ed.)


name: Anal Cancer Pathologic Primary Tumor TNM Finding v8

description: A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.


name: Anal Cancer Pathologic Regional Lymph Nodes TNM Finding v8

description: A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.


name: Anal Cancer Pathologic Distant Metastasis TNM Finding v8

description: A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.


Anal Cancer pT1 TNM Finding v8

description: Anal cancer with tumor 2 cm or smaller. (from AJCC 8th Ed.)


Anal Cancer pN1a TNM Finding v8

description: Anal cancer with metastasis in inguinal, mesorectal, or internal iliac lymph nodes. (from AJCC 8th Ed.)


Anal Cancer pT0 TNM Finding v8

description: Anal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)


Grade 2 Lip Infection, CTCAE

description: Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)


Ala-Eth

A dipeptide formed from L-alanyl and L-ethionine residues.


Moniliform hamartoma

description: A type of pilosebaceous hamartoma characterized by the development of a linear, flesh colored, fine papular eruption on the head, neck and upper chest after puberty.


Apocrine Sweat Gland Hamartoma

description: A hamartoma characterized by localized apocrine sweat gland malformation.


name: Merkel Cell Carcinoma pN1b TNM Finding v7

description: Merkel cell carcinoma with macrometastasis in regional lymph node(s).  Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or needle biopsy. (from AJCC 7th Ed.)


name: Recurrent Endometrial Undifferentiated Carcinoma

description: The reemergence of endometrial undifferentiated carcinoma after a period of remission.


name: Metastatic Endometrial Undifferentiated Carcinoma

description: Endometrial undifferentiated carcinoma that has spread from its original site of growth to another anatomic site.


name: Refractory Endometrial Undifferentiated Carcinoma

description: Endometrial undifferentiated carcinoma that is resistant to treatment.


name: Esophageal Gastrointestinal Stromal Tumor

description: A gastrointestinal stromal tumor that arises from the esophagus.  The majority are spindle cell tumors that exhibit high mitotic activity and affect the distal esophagus.


name: 2-(2-methyl-1-benzimidazolyl)acetic acid [2-(2-methyl-1H-indol-3-yl)-2-oxoethyl] ester


Grade 4 Retinopathy, CTCAE

description: Best corrected visual acuity of 20/200 or worse in the affected eye


name: Rheumatoid Polyneuropathy with Rheumatoid Arthritis of Unspecified Hand

description: Evidence of rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand.


An alpha-hydroxyglycine that has S configuration.


alpha-hydroxyglycine

A hydroxy-amino acid that is glycine substituted by a hydroxy group at the alpha-position.


An N-acyl-(2S)-hydroxyglycine resulting from the formal condensation of dodecanoic acid (lauric acid) with the amino group of (2S)-hydroxyglycine.


Grade 2 Wrist Fracture, CTCAE

description: Limiting instrumental ADL; outpatient operative intervention indicated


ISOBUTYLBENZENE

An alkylbenzene that is benzene carrying an isobutyl substituent.


name: 6,6-dimethyl-4-oxo-3-(phenylmethylthio)-5,7-dihydro-2-benzothiophene-1-carboxylic acid ethyl ester


name: Colorectal Neuroendocrine Tumor pT2 TNM Finding v8

description: Colorectal neuroendocrine tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa.  (from AJCC 8th Ed.)


Grade 2 Neonatal Fever, AE

description: An adverse event in a newborn characterized by fever, minor change in baseline age-appropriate behavior; minor changes in care (e.g. environmental settings, symptomatic treatment).


Tyr-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-threonine.


A benzamide that is GRL-0617 in which one of the hydrogen's of the primary amino group is replaced by an acetyl group. It an inhibitor of SARS-CoV and SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 2.6 muM and 5.0 muM, respectively. It also inhibits SARS-CoV and SARS-CoV-2 infection of Vero E6 cells in vitro (EC50 values are 13.1 and 21 muM, respectively).


A pyridone that is 6-oxo-1,6-dihydropyridine-2-carboxylic acid substituted by a 2-carboxyethyl group at position 5.


name: Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Oral cavity cancer with very advanced local disease.  Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IVB Lip and Oral Cavity Cancer AJCC v6 and v7

description: Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Lip and oral cavity cancer with very advanced local disease.  Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7


name: Stage IVB Oral Cavity Mucoepidermoid Carcinoma AJCC v6 and v7


name: Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

description: Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Lip and oral cavity cancer with very advanced local disease. Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


name: Stage IVB Oral Cavity Cancer AJCC v6 and v7


Stage IVB Lip Cancer AJCC v6 and v7

description: Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Lip cancer with very advanced local disease.  Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)


omega-hydroxyoctacosanoic acid

An omega-hydroxy fatty acid that is octacosanoic acid substituted by a hydroxy group at position 28.


name: Follicular Lymphoma Grade IIIb, Intra-abdominal Lymph Nodes

description: Evidence of follicular lymphoma grade IIIb in the intra-abdominal lymph nodes.


Grade 1 Oropharyngeal Pain, CTCAE

description: Mild pain


Grade 2 Premature Menopause, CTCAE

description: Present


methyl beta-D-glucopyranoside

A beta-D-glucopyranoside having a methyl substituent at the anomeric position.


α-MDG

An alpha-D-glucopyranoside having a methyl substituent at the anomeric position.


fusahexin

A cyclic hexapeptide with the amino acid sequence cyclo-(D-Ala-L-Leu-D-allo-Thr-L-Pro-D-Leu-L-Leu). Fusahexin is a secondary metabolite produced by the plant pathogenic fungus Fusarium graminearum.


name: Grade 5 Pharynx Obstruction and Stenosis, CTCAE


A hydroxycoumarin that is 4,7-dihydroxycoumarin bearing an additional amino substituent at positions 3.


A purine 2'-deoxyribonucleoside 5'-monophosphate having 6-O-benzylguanine as the nucleobase.


flutrimazole

An imidazole antifungal agent that is imidazole in which the hydrogen attached to the nitrogen is replaced by a 2,4'-difluorotrityl group. A topical antifungal agent which displays potent broad-spectrum in vitro activity against dermatophytes, filamentous fungi and yeasts.


name: Pathologic Stage IB Cutaneous Melanoma AJCC v8

description: Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)


Vein of Galen Malformations

description: An arteriovenous malformation in the vein of Galen that is located at the base of the brain. The malformation may result in developmental delays, hydrocephalus, seizures, and congestive heart failure.


Grade 1 Tracheal Hemorrhage, CTCAE

description: Mild symptoms; intervention not indicated


An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2-trans,4-cis)-deca-2,4-dienoic acid.


name: Dextro-Transposition of the Great Vessels with Ventricular Septal Defect

description: A congenital heart defect in which there is an abnormal arrangement of any of the primary blood vessels of the heart in conjunction with a pathologic opening between the cardiac ventricles.


phenosafranine

An organic chloride salt having 3,7-diamino-5-phenylphenazin-5-ium as the counterion. It is commonly used for staining Gram negative bacteria red in smears to contrast with the blue Gram positive organisms.


Grade 2 Retinopathy of Prematurity, AE

description: An adverse event in a newborn characterized by type 2 prethreshold retinopathy of prematurity (ROP) (zone 1 International Classification of Retinopathy of Prematurity (ICROP) stage 1 or 2 without plus disease; zone 2 ICROP stage 3 without plus disease); requiring more frequent ophthalmic monitoring.


JASPAMIDE L

A cyclodepsipeptide isolated from Jaspis splendens. A derivative of jaspamide, it has been shown to exhibit cytotoxic and microfilament disruption activity.


name: Grade 2 Intestinal Stoma Obstruction, CTCAE

description: Self-limited; intervention not indicated


arthothelin

A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3 and 6, chloro groups at positions 2, 4 and 5 and a methyl group at position 8. It has been isolated from the lichen, Lecanora iseana.


name: 3-(3-methoxyphenyl)-2-propenoic acid [2-oxo-2-[4-(1-pyrrolidinylsulfonyl)anilino]ethyl] ester


heptylmalonic acid

A dicarboxylic acid that is malonic acid substituted with a heptyl group at position C-2.


His-Tyr

A dipeptide formed from L-histidine and L-tyrosine residues.


Ile-Lys

A dipeptide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of L-lysine.


gamma-Glu-His

A glutamyl-L-amino acid obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of histidine.


Gly-Leu

A dipeptide composed of glycine and L-leucine joined by a peptide linkage.


Arg-Phe

A dipeptide formed from L-arginine and L-phenylalanine residues. It exhibits vasorelaxant activity.


Glu-Glu

A dipeptide composed of two L-glutamic acid units joined by a peptide linkage.


Asn-Ile

A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-isoleucine.


Ile-Pro

A dipeptide formed from L-isoleucine and L-proline residues.


Glu-Cys

A dipeptide composed of L-glutamic acid and L-cysteine joined by a peptide linkage.


Phe-Asn

A dipeptide composed of L-phenylalanine and L-asparagine joined by a peptide linkage.


Trp-Val

A dipeptide formed from L-tryptophan and L-valine residues.


gamma-Glu-Glu

A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of another glutamic acid.


A dipeptide that consists of beta-alanyl-L-glutamine amide bearing a 2-carboxy-4,6-dinitrophenyl (DNCP) substituent at the amino terminus while the amides at the carboxy terminus and side-chain are substituted by beta-D-glucopyranos-2-yl groups.


Thr-Ile

A dipeptide obtained by formal condensation of the carboxy group of L-threonine with the amino group of L-isoleucine.


Ile-Gln

A dipeptide formed from L-isoleucine and L-glutamine residues.


gammaGluCys(IAN)

An S-conjugate dipeptide consisting of L-gamma-glutamyl-L-cysteine in which the the cysteine side chain is substituted by a cyano(indol-3-yl)methyl group.


Pro-Leu

A dipeptide formed from L-proline and L-leucine residues.


Met-Met

A dipeptide formed from two L-methionine residues.


Leu-Gly

A dipeptide formed from L-leucine and glycine residues.


Gly-His

A dipeptide composed of glycine and L-histidine joined by a peptide linkage.


Ile-Ala

A dipeptide formed from L-isoleucine and L-alanine residues.


Gly-Ile

A dipeptide formed from glycine and L-isoleucine residues.


The dipeptide obtained by coupling N-benzyloxycarbonyl-L-tyrosine with the hydroxamic acid derivative of L-leucine. It is an inhibitor of the metallo-protease enzyme, pseudolysin (EC 3.4.24.36).


GLUTAURINE

A dipeptide resulting from the formal condensation of the amino group of taurine with the gamma-carboxy group of L-glutamic acid. It was initially found in the parathyroid in 1980 and later in the brain of mammals.


cyclo(tyrosyl-tyrosyl)

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by p-hydroxybenzyl groups.


A docosanoid that is (14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid in which a cysteinylglycinyl group is attached at position 13R via a sulfide linkage.


Gln-Leu

A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of L-leucine.


Tyr-Cys

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-cysteine.


Met-FMDP

A  dipeptide  composed of 3-{[(2E)-4-methoxy-4-oxobut-2-enoyl]amino}alanine and L-methionine joined by peptide linkages.


Pro-Asp

A dipeptide formed from L-proline and L-aspartic acid residues.


tabtoxin

A monobactam phytotoxic dipeptide produced by Pseudomonas syringae, that causes wildfire disease in tobacco.


Arg-Arg

A dipeptide formed from two L-arginine residues.


Met-Asp

A dipeptide formed from L-methionine and L-aspartic acid residues.


deoxybrevianamide E

A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a 1,1-dimethylallyl group.


Lys-Gly

A dipeptide formed from L-lysine and glycine residues.


An S-conjugate in which the mercapto hydrogen of L-cysteinylglycine has been replaced by an N-hydroxy-2-(indol-3-yl)ethanimidoyl group.


Phe-Thr

A dipeptide composed of L-phenylalanine and L-threonine joined by a peptide linkage.


Met-beta-Ala

A dipeptide formed from L-methionine and beta-alanine residues.


A dipeptide formed from L-valine and L-phenylalanine residues.


D-Leu-Gly

A dipeptide formed from D-leucine and glycine residues.


Asp-Trp

A dipeptide formed from L-alpha-aspartyl and L-tryptophan residues.


Lys-Leu

A dipeptide formed from L-lysine and L-leucine residues.


Gly-Ala

A dipeptide formed from glycine and L-alanine residues.


dapdiamide E

A member of the family of dapdiamides consisting of 3-aminoalanylvaline, in which the N-terminus is acylated by a 3-carbamoyloxirane-2-carbonyl group. NB Although the relative configuration of the epoxide moiety has been assigned as trans, it has not yet been established whether the absolute configuration is R,R (as drawn) or S,S.


Ser-Ala

A dipeptide formed from L-serine and L-alanine residues.


bacilysin

A non-ribosomally synthesised dipeptide that consists of L-alanyl and anticapsin units linked by a peptide bond.


A docosanoid that is (7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid in which a cysteinylglycinyl group is attached at position 8S via a sulfide linkage. An intermediate of specialised proresolving mediators.


TRYPROSTATIN B

A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a prenyl group.


Ala-Ser

A dipeptide composed of L-alanine and L-serine joined by a peptide linkage.


Asp-Arg

A dipeptide composed of L-aspartic acid and L-arginine joined by a peptide linkage.


gamma-Glu-Trp

A glutamyl-L-amino acid obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of tryptophan.


Thr-His

A dipeptide composed of L-threonine and L-histidine joined by a peptide linkage.


Gly-Trp

A dipeptide formed from glycine and L-tryptophan residues.


Tyr-Lys

A dipeptide formed from L-tyrosine and L-lysine residues.


Phe-Glu

A dipeptide formed from L-phenylalanine and L-glutamic acid residues.


Gln-Trp

A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of  L-tryptophan.


Pro-Arg

A dipeptide formed from L-proline and L-arginine residues.


Asn-Glu

A dipeptide formed from L-asparagine and L-glutamic acid residues.


Arg-Gln

A dipeptide formed from L-arginyl and L-glutamine residues.


Asn-Ser

A dipeptide composed of L-asparagine and L-serine joined by a peptide linkage.


A dipeptide consisting of N-butyl-L-cysteinamide having an (R)-2-amino-2-(4-hydroxyphenyl)acetyl residue attached to its alpha-amino nitrogen.


Dnp-Trp-Gln

A dipeptide consisting of L-tryptophan substituted on the alpha-nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.


N-acetyl-L-seryl-L-aspartic acid

A dipeptide formed from N-acetyl-L-seryl and L-aspartic acid residues.


Major microspecies at pH 7.3.


chrysobactin

A catechol-type siderophore with a structure of D-lysyl-L-serine substituted on N(2) of the lysyl residue by a 2,3-dihydroxybenzoyl group. It is produced by the Gram-negative bacillus Dickeya dadantii (previously known as Erwinia chrysanthem). Only the catecholate hydroxyl groups participate in metal coordination, so chrysobactin cannot provide full 1:1 coordination of Fe(III); at neutral pH and concentrations of about 0.1 mM, ferric chrysobactin exists as a mixture of bis and tris complexes.


VANCHROBACTIN

A catechol-type natural product that is composed of 2,3-dihydroxybenzoic acid, D-arginine and L-serine joined in sequence by peptide linkages. It is a siderophore synthesized by the bacterial fish pathogen Vibrio anguillarum.


Cys-Ser

A dipeptide composed of L-cysteine and L-serine joined by a peptide linkage.


Gln-Asn

A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of  L-asparagine.


Asn-Val

A dipeptide formed from L-asparagine and L-valine residues.


Thr-Glu

A dipeptide formed from L-threonine and L-glutamic acid residues.


beta-Asp-Leu

A dipeptide that is the N-(L-beta-aspartyl) derivative of L-leucine.


Tyr-FMDP

A dipeptide composed of 3-{[(2E)-4-methoxy-4-oxobut-2-enoyl]amino}alanine and L-tyrosine joined by peptide linkages.


L-lysyl-D-alanine

A dipeptide formed from L-lysyl and D-alanyl residues.


A dipeptide composed of L-leucine and L-methioninamide units joined by a peptide linkage. It is a noncompetitive inhibitor of Gap1 transport.


Leu-Cys

A dipeptide composed of L-leucine and L-cysteine joined by a peptide linkage.


Tyr-Gln

A dipeptide formed from L-tyrosine and L-glutamine residues.


Pro-Lys

A dipeptide formed from L-proline and L-lysine residues.


cyclo(L-phenylalanyl-L-phenylalanyl)

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by benzyl groups (the 3S,6S-diastereomer).


Val-Tyr

A dipeptide formed from L-valine and L-tyrosine residues.


A dipeptide consisting of N-butyl-L-cysteinamide having an (R)-2-amino-2-phenylacetyl residue attached to its alpha-amino nitrogen.


L-alanyl-L-alanine

A dipeptide consisting of two L-alanine units joined by a peptide linkage.


PLINABULIN

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione substituted by benzylidene and (5-tert-butyl-1H-imidazol-4-yl)methylidene groups at positions 3 and 6, respectively. It is a vascular disrupting agent and a microtubule destabalising agent which was in clinical trials (now discontinued) for the treatment of non-small cell lung cancer.


Trp-Leu

A dipeptide formed from L-tryptophan and L-leucine residues.


A dipeptide obtained by formal condensation of the carboxy group of 4-chloro-L-phenylalanine with the amino group of glycine.


L-Lys-D-Asp

A dipeptide obtained by formal condensation of the carboxy group of L-lysine with the amino group of D-aspartic acid. It is a constituent of bacterial peptidoglycan type A4alpha.


His-His

A dipeptide formed from two L-histidine residues.


beta-Asp-Glu

A dipeptide consisting of an L-aspartyl residue attached to L-glutamic acid via the beta-carboxy group.


N-formyl-L-methionyl-L-methionine

A dipeptide that is L-methionyl-L-methionine (Met-Met) in which the nitrogen of the N-terminal amino group has been converted into the corresponding formamide.


Gly-Phe

A dipeptide formed from glycine and L-phenylalanine residues.


Thr-Gly

A dipeptide formed from L-threonine and glycine residues.


Trp-Ser

A dipeptide formed from L-tryptophan and L-serine residues.


Asn-Asp

A dipeptide composed of L-asparagine and L-aspartic acid joined by a peptide linkage.


Ala-Thr

A dipeptide formed from L-alanyl and L-threonine residues.


A dipeptide resulting from the formal coupling of the carboxy group of N(2)-(diphenylacetyl)-D-arginine with the alpha-amino group of D-2-phenylglycinamide.


Ile-Met

A dipeptide formed from L-isoleucine and L-methionine residues.


Ala-Asn

A dipeptide composed of L-alanine and L-asparagine units joined by a peptide linkage.


Gly-Asp

A dipeptide formed from glycyl and L-aspartic acid residues.


Lys-Phe

A dipeptide formed from L-lysine and L-phenylalanine residues.


Ser-Asp

A dipeptide formed from L-serine and L-aspartic acid residues.


Ser-Asn

A dipeptide formed from L-serine and L-asparagine residues.


A dipeptide resulting from the formal condensation of the carboxy group of L-alpha-aminobutyric acid [(2S)-2-aminobutanoic acid] with the amino group of glycine.


Glu-Thr

A dipeptide composed of L-glutamic acid and L-threonine joined by a peptide linkage.


Dnp-Asn-Gln

A dipeptide consisting of L-asparagine substituted on the alpha-nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.


Gly-Arg

A dipeptide formed from glycine and L-arginine residues.


Trp-Gly

A dipeptide formed from L-tryptophan and glycine residues.


Leu-Ser

A dipeptide formed from L-leucine and L-serine residues.


Glu-Val

A glutamyl-L-amino acid that is the N-(L-alpha-glutamyl) derivative of L-leucine.


Met-Ala

A dipeptide formed from L-methionine and L-alanine residues.


Trp-Ala

A dipeptide formed from L-tryptophan and L-alanine residues.


A dipeptide in which the carboxy group of L-homocysteine forms an amide bond with the alpha-nitrogen of N(epsilon)-acetylated L-lysine.


Trp-Asp

A dipeptide formed from L-tryptophan and L-aspartic acid residues.


Ala-Cys

A dipeptide obtained by formal condensation of the carboxy group of L-alanine with the amino group of L-cysteine.


Ser-Glu

A dipeptide formed from L-serine and L-glutamic acid residues.


Met-Ser

A dipeptide composed of L-methionine and L-serine joined by a peptide linkage.


Met-Lys

A dipeptide formed from L-methionine and L-lysine residues.


His-Leu

A dipeptide formed from L-histidine and L-leucine residues.


Ser-Trp

A dipeptide obtained by formal condensation of the carboxy group of L-serine with the amino group of L-tryptophan.


A dipeptide formed from L-arginine and L-phenylalaninamide residues in which a hydrogen attached to the nitrogen of the alpha-amino group of the arginine residue has been replaced by a 1-adamantanecarbonyl group. It has been reported to be a potent and selective antagonist of neuropeptide FF (NPFF) receptors, but more recently found to be an agonist at both NPFF1R and the kisspeptin receptor (KISS1R).


L-seryl-L-tyrosine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of L-seryl-L-tyrosine with the amino group of 2-naphthylamine.


Leu-Tyr

A dipeptide formed from L-leucine and L-tyrosine residues.


Ile-Trp

A dipeptide formed from L-isoleucine and L-tryptophan residues.


A dipeptide that is glutathione in which the amino group on the glutamyl residue has been replaced by an oxo group.


A dipeptide consisting of L-tyrosine substituted on nitrogen and oxygen by 2,4-dinitrophenyl groups and connected to L-glutamine via a peptide bond.


Trp-Arg

A dipeptide formed from L-tryptophan and L-arginine residues.


Leu-Trp

A dipeptide formed from L-leucine and L-tryptophan residues.


D-Leu-D-Leu

A dipeptide formed from two D-leucine residues.


Ser-Tyr

A dipeptide formed from L-serine and L-tyrosine residues.


dapdiamide C

A member of the family of dapdiamides consisting of alanylleucine, in which one of the methyl hydrogens of alanine is replaced by a fumaramoyl group.


beta-alanyl-L-lysine

A dipeptide consisting of beta-alanine and L-lysine units joined by a peptide linkage.


Met-Phe

A dipeptide formed from L-methionine and L-phenylalanine residues.


Met-Val

A dipeptide formed from L-methionine and L-valine residues.


Tyr-Leu

A dipeptide formed from L-tyrosine and L-leucine residues.


His-Phe

A dipeptide obtained by formal condensation of the carboxy group of L-histidine with the amino group of L-phenylalanine.


gamma-glutamylthreonine

A dipeptide composed of glutamic acid and  threonine joined by a peptide linkage.


gamma-Glu-Abu

A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of 2-aminobutyric acid.


cyclo(DeltaAla-L-Val)

A 2,5-diketopiperazine where the substituents are methylidene and (S)-isopropyl at positions  3 and 6 respectively.


Cys-Pro

A dipeptide composed of L-cysteine and L-proline joined by a peptide linkage.


Gly-Ser

A dipeptide composed of glycine and L-serine joined by a peptide linkage.


Pro-Met

A dipeptide obtained by formal condensation of the carboxy group of L-proline with the amino group of L-methionine.


Glu-Arg

A dipeptide composed of L-glutamic acid and L-arginine joined by a peptide linkage.


Asp-Met

A dipeptide obtained by formal condensation of the carboxy group of L-aspartic acid  with the amino group of L-methionine.


beta-Ala-Gly

A dipeptide formed from beta-alanine and glycine residues.


Ile-Asn

A dipeptide formed from L-isoleucine and L-asparagine residues.


Trp-Phe

A dipeptide formed from L-tryptophan and L-phenylalanine residues.


Arg-Lys

A dipeptide formed from L-arginyl and L-leucine residues.


His-Glu

A dipeptide formed from L-histidine and L-glutamic acid residues.


D-Leu-Tyr

A dipeptide formed from D-leucine and L-tyrosine residues.


bis-gamma-glutamylcystine

The dimer obtained by formal oxidative coupling of gamma-glutamylcystine.


Asn-His

A dipeptide composed of L-asparagine and L-histidine joined by a peptide linkage.


Leu-Pro

A dipeptide formed from L-leucine and L-proline residues.


Met-Trp

A dipeptide formed from L-methionine and L-tryptophan residues.


Ala-Lys

A dipeptide obtained by formal condensation of the carboxy group of L-alanine with the alpha-amino group of L-lysine.


Arg-Ser

A dipeptide formed from L-arginine and L-serine residues.


Thr-Pro

A dipeptide formed from L-threonine and L-proline residues.


Ala-Val

A dipeptide formed from L-alanyl and L-valine residues.


gamma-Glu-Phe

A dipeptide obtained by formal condensation of the side-chain carboxy group of L-glutamic acid with the amino group of L-phenylalanine.


glycyl-L-tryptophan 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycyl-L-tryptophan with the amino group of 2-naphthylamine.


Tyr-Phe

A dipeptide formed from L-tyrosine and L-phenylalanine residues.


Asp-Asp

A dipeptide formed from two L-aspartic acid units.


D-alanyl-D-serine

A dipeptide comprising D-serine with a D-alanyl residue attached to the alpha-nitrogen.


Glu-Tyr

A dipeptide composed of L-glutamic acid and L-tyrosine joined by a peptide linkage.


Lys-Thr

A dipeptide formed from L-lysine and L-threonine residues.


Major species at pH 7.3.


Ala-Asp

A dipeptide formed from L-alanyl and L-aspartic acid residues.


Pro-Gln

A dipeptide formed from L-proline and L-glutamine residues.


CORDYSININ A

A pyrrolopyrazine that is hexahydropyrrolo[1,2-a]pyrazine-1,4-dione substituted by a hydroxy group at position 6 and a 2-methylpropyl group at position 3. It has been isolated from the mycelia of Cordyceps sinensis.


Pro-Phe

A dipeptide formed from L-proline and L-phenylalanine residues.


Glu-Ala

A dipeptide formed from L-alpha-glutamyl and L-alanine residues.


ANSERINE

A dipeptide comprising of beta-alanine and 3-methyl-L-histidine units.


3,5-Diiodotyrosyl-3,5-diiodotyrosine in which each tyrosine residue has L-configuration.


neoechinulin B (anion)

Major microspecies at pH 7.3.


Phe-Trp

A dipeptide formed from L-phenylalanine and L-tryptophan residues.


Asp-Phe

A dipeptide formed from L-alpha-aspartyl and L-phenylalanine residues. It is obtained after the hydrolysis of aspartame in intestinal lumen.


Leu-Asn

A dipeptide composed of L-leucine and L-asparagine joined by a peptide linkage.


Asn-Gln

A dipeptide composed of L-asparagine and L-glutamine joined by a peptide linkage.


Ser-Leu

A dipeptide formed from L-serine and L-leucine residues.


Val-Ser

A dipeptide formed from L-valine and L-serine residues.


Val-Arg

A dipeptide formed from L-valine and L-asparagine residues.


Arg-Tyr

A dipeptide formed from L-arginine and L-tyrosine residues.


S-nitroso-L-cysteinylglycine

A dipeptide resulting from the formal condensation of the carboxylic acid group of S-nitroso-L-cysteine with the amino group of glycine.


Leu-FMDP

A  dipeptide  composed of 3-{[(2E)-4-methoxy-4-oxobut-2-enoyl]amino}alanine and L-leucine joined by peptide linkages.


Ile-His

A dipeptide composed of L-isoleucine and L-histidine joined by a peptide linkage.


Leu-Met

A dipeptide formed from L-leucine and L-methionine residues.


isotabtoxin

A dipeptide obtained by formal condensation of the carboxy group of (2S,5S)-5-(aminomethyl)-5-hydroxy-6-oxopiperidine-2-carboxylic acid (tabtoxinine-delta-lactam) with the amino group of L-threonine.


Gly-D-Ser

A dipeptide formed from glycine and D-serine residues.


glycyl-L-proline 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycyl-L-proline with the amino group of 2-naphthylamine.


His-Met

A dipeptide formed from L-histidine and L-methionine residues.


Asp-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-aspartic acid with the amino group of L-threonine.


D-gamma-Glu-Gly

A dipeptide formed from D-gamma-glutamyl and glycine residues.


Asp-Val

A dipeptide formed from L-alpha-aspartyl and L-valine residues.


His-Asp

A dipeptide formed from L-histidine and L-aspartic acid residues.


Glu-Leu

A dipeptide composed of L-glutamic acid and L-leucine joined by a peptide linkage.


Gln-Phe

A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of L-phenylalanine.


Dnp-Sar-Gln

A dipeptide consisting of sarcosine (1-methylglycine) substituted on nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.


Phe-Leu

A dipeptide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of L-leucine.


Asn-Met

A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-methionine.


Lys-Asp

A dipeptide formed from L-lysine and L-aspartic acid residues.


Glu-Pro

A dipeptide composed of L-glutamic acid and L-proline joined by a peptide linkage.


Met-Pro

A dipeptide formed from L-methionine and L-proline residues.


Phe-Ser

A dipeptide that is the N-(L-phenylalanyl) derivative of L-serine.


Ser-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-serine with the amino group of L-threonine.


Pro-Ile

A dipeptide formed from L-proline and L-isoleucine residues.


Lys-Pro

A dipeptide formed from L-lysine and L-proline residues.


Lys-Gln

A dipeptide composed of L-lysine and L-glutamine joined by a peptide linkage.


Thr-Asn

A dipeptide obtained by formal condensation of the carboxy group of L-threonine with the amino group of L-asparagine.


spiraprilat

An azaspiro compound that is spirapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid group. It is the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor spirapril.


Met-Glu

A dipeptide formed from L-methionine and L-glutamic acid residues.


dapdiamide B

A member of the family of dapdiamides consisting of alanylisoleucine, in which one of the methyl hydrogens of alanine is replaced by a fumaramoyl group.


Ile-Tyr

A dipeptide formed from L-isoleucine and L-tyrosine residues.


dapdiamide A

A member of the family of dapdiamides consisting of alanylvaline in which one of the methyl hydrogens of alanine is replaced by a fumaramoyl group.


gamma-glutamyl-beta-cyanoalanine

A dipeptide composed of 3-cyano-L-alanine and L-glutamine joined by a peptide linkage formed from the side-chain of glutamine.


Ser-Pro

A dipeptide formed from L-serine and L-proline residues.


Ile-Val

A dipeptide formed from L-isoleucine and L-valine residues.


Gln-Gly

A dipeptide formed from L-glutamine and glycine residues.


isoechinulin B anion

Major microspecies at pH 7.3.


A member of the class of 2,5-diketopiperazines that is piperazine substituted by oxo groups at positions 2 and 5, and by a methyl group at position 3.


A dipeptide consisting of N-butyl-L-alaninamide having an (R)-2-amino-2-(4-hydroxyphenyl)acetyl residue attached to its alpha-amino nitrogen.


Trp-Pro

A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-proline.


Val-Ala

A dipeptide formed from L-valine and L-alanine residues.


Met-Tyr

A dipeptide formed from L-methionine and L-tyrosine residues.


Leu-His

A dipeptide formed from L-leucine and L-histidine residues.


His-Pro

A dipeptide formed from L-histidine and L-proline residues.


Phe-Lys

A dipeptide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of L-lysine.


Val-Leu

A dipeptide formed from L-valine and L-leucine residues.


Pro-Trp

A dipeptide formed from L-proline and L-tryptophan residues.


Ile-Phe

A dipeptide formed from L-isoleucine and L-phenylalanine residues.


Pro-Ala

A dipeptide formed from L-proline and L-alanine residues.


Lys-Arg

A dipeptide formed from L-lysine and L-arginine residues.


Trp-Glu

A dipeptide formed from L-tryptophan and L-glutamic acid residues.


A non-proteinogenic dipeptide anion formed from the (3R)-hydroxylation of L-gamma-glutamyl-L-propargylglycine(1-). Major species at pH 7.3.


Trp-Tyr

A dipeptide formed from L-tryptophan and L-tyrosine residues.


Gly-Gln

A dipeptide formed from glycine and L-glutamine residues.


Leu-Arg

A dipeptide composed of L-leucine and L-arginine joined by peptide linkages.


Gly-Met

A dipeptide formed from glycine and L-methionine residues.


Phe-FMDP

A dipeptide composed of 3-{[(2E)-4-methoxy-4-oxobut-2-enoyl]amino}alanine and L-phenylalanine joined by peptide linkages.


L-tryptophan polyoxin C

Polyoxin C in which the primary amino group has been condensed with L-tryptophan to form a peptide bond.


Leu-Lys

A dipeptide composed of L-leucine and L-lysine joined by a peptide linkage.


7-dimethylallyl isoechinulin B anion

Major microspecies at pH 7.3.


His-Lys

A dipeptide formed from L-histidine and L-lysine residues.


Asp-His

A dipeptide composed of L-aspartic acid and L-histidine joined by a peptide linkage.


beta-Asp-Ile

A dipeptide that is the N-(L-beta-aspartyl) derivative of L-isoleucine.


Dnp-Nor-Gln

A dipeptide consisting of L-norvaline substituted on nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.


cyclo(L-tyrosyl-L-phenylalanyl)

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by benzyl and 4-hydroxybenzyl groups (the 3S,6S-diastereomer).


Arg-Val

A dipeptide formed from L-arginine and L-valine residues.


His-Ile

A dipeptide obtained by formal condensation of the carboxy group of L-histidine with the amino group of L-isoleucine.


A dipeptide consisting of a modified L-proline residue attached to L-alanine via a peptide linkage.


D-gamma-glutamyl-D-glutamic acid

A dipeptide consisting of a D-gamma-glutamyl residue attached to D-glutamic via a peptide linkage.


Gly-Thr

A dipeptide formed from glycine and L-threonine residues.


Asp-Tyr

A dipeptide composed of L-aspartic acid and L-tyrosine joined by a peptide linkage.


cyclo(L-phenylalanyl-L-leucyl)

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by benzyl and isobutyl groups (the 3S,6S-diastereomer).


Cys-Arg

A dipeptide obtained by formal condensation of the carboxy group of L-cysteine with the amino group of L-arginine.


A dipeptide consisting of L-phenylalanine nitro-substituted at C-4 of the phenyl ring and connected to L-glutamine via a peptide bond.


glioperazine B

A member of the class of 2,5-diketopiperazines with an indole substituent. It is a microbial metabolite isolated from the mycelia of a liquid fermentation culture of the fungus, Bionectria byssicola and has been shown to exhibit antibacterial activity against Staphylococcus aureus.


Gly-Lys

A dipeptide formed from glycine and L-lysine residues.


Ala-Ile

A dipeptide formed from L-alanyl and L-isoleucine residues.


VAL-VAL

A dipeptide formed from two L-valine residues.


fellutanine

A member of the class of  2,5-diketopiperazines that is piperazine-2,5-dione substituted by 1H-indol-3-ylmethyl groups at positions 3 and 6 respectively. Isolated from  Penicillium species, it exhibits antibacterial activity.


Leu-Phe

A dipeptide formed from L-leucine and L-phenylalanine residues.


Ser-Ser

A dipeptide formed from two L-serine residues.


Tyr-Ile

A dipeptide formed from L-tyrosine and L-isoleucine residues.


TRYPROSTATIN A

A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and methoxy groups respectively.


Phe-beta-Ala

A dipeptide formed from L-phenylalanine and beta-alanine residues.


Asn-Gly

A dipeptide composed of L-asparagine and glycine joined by a peptide linkage.


L-Lys-D-Glu

A dipeptide obtained by formal condensation of the carboxy group of L-lysine with the amino group of D-glutamic acid. It is a constituent of bacterial peptidoglycan type A4alpha.


Ser-Phe

A dipeptide that is the N-(L-seryl) derivative of L-phenylalanine.


Phe-Val

A dipeptide formed from L-phenylalanine and L-valine residues.


Met-Asn

A dipeptide obtained by formal condensation of the carboxy group of L-methionine with the amino group of L-asparagine.


Lys-Trp

A dipeptide formed from L-lysine and L-tryptophan residues.


Arg-Trp

A dipeptide formed from L-arginine and L-tryptophan residues.


beta-Ala-Ala

A dipeptide formed from beta-alanine and L-alanine residues.


Gln-Gln

A dipeptide formed from two L-glutamine residues.


Ala-His

A dipeptide formed from L-alanyl and L-histidine residues.


Asp-Lys

A dipeptide formed from L-alpha-aspartyl and L-lysine residues.


Asn-Phe

A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-phenylalanine.


gamma-Glu-Met

A dipeptide composed of L-glutamic acid and L-methionine joined by a peptide linkage.


Gly-Val

A dipeptide formed from glycine and L-valine residues.


Thr-Val

A dipeptide obtained by formal condensation of the carboxy group of L-threonine with the amino group of L-valine.


Thr-Trp

A dipeptide composed of L-threonine and L-tryptophan joined by a peptide linkage.


Major microspecies at pH 7.3.


L-gamma-Glu-L-Thr

A dipeptide obtained by formal condensation of the side-chain carboxy group of L-glutamic acid with the amino group of L-threonnine.


ficellomycin

A dipeptide antibiotic containing an azabicyclohexane ring system that exhibits potent in vitro activity against Penicillium oxalicum and Staphylococcus aureus. It inhibits semi-conservative DNA replication by causing accumulation of 34S DNA species.


Ser-Lys

A dipeptide composed of L-serine and L-lysine joined by a peptide linkage. It is a constituent of bacterial cell wall peptidoglycan type A11.14 and A3alpha.


Gly-Cys

A dipeptide formed from glycine and L-cysteine residues.


gamma-glutamylphenylalanine

A dipeptide composed of glutamic acid and phenylalanine joined together by a peptide linkage.


Thr-Asp

A dipeptide formed from L-threonine and L-aspartic acid residues.


L-glutamylglycine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the C-terminal carboxy group of L-glutamylglycine with the amino group of 2-naphthylamine.


Dnp-Thr-Gln

A dipeptide consisting of L-threonine substituted on nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.


Gly-Glu

A dipeptide formed from glycyl and L-glutamic acid residues.


Gln-Glu

A dipeptide formed from L-glutamine and L-glutamic acid residues.


Asp-Ser

A dipeptide composed of L-aspartic acid and L-serine joined by a peptide linkage.


beta-Ala-Phe

A dipeptide formed from beta-alanine and L-phenylalanine residues.


Ile-Leu

A dipeptide formed from L-isoleucine and L-leucine residues.


glycyl-L-phenylalanine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycyl-L-phenylalanine with the amino group of 2-naphthylamine.


Tyr-Tyr

Tyrosyltyrosine in which each tyrosine residue has L-configuration.


Thr-Phe

A dipeptide formed from L-threonine and L-phenylalanine residues.


neotame

A dipeptide composed of N-(3,3-dimethylbutyl)-L-aspartic acid and methyl L-phenylalanate units joined by a peptide linkage.


pyroglutamylvaline

A dipeptide obtained by formal condensation of the carboxy group of pyroglutamic acid with the amino group of valine.


gamma-Glu-Gln

A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of glutamine


Tyr-Asp

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-aspartic acid.


BREVIANAMIDE F

A pyrrolopyrazine that is hexahydropyrrolo[1,2-a]pyrazine-1,4-dione bearing an indol-3-ylmethyl substituent at position 3 (the 3S,8aS-diastereomer, obtained by formal cyclocondensation of L-tryptophan and L-proline).


A dipeptide composed of N-acetyl-L-phenylalanine and 3,5-diiodo-L-tyrosine joined together by a peptide linkage. It is a synthetic substrate for pepsin.


Val-Pro

A dipeptide formed from L-valine and L-proline residues.


Glu-Lys

A dipeptide composed of L-glutamic acid and L-lysine joined by a peptide linkage.


Glu-Gly

A dipeptide composed of L-glutamic acid and glycine joined by a peptide linkage.


Leu-beta-Ala

A dipeptide formed from L-leucine and beta-alanine residues.


Thr-Lys

A dipeptide obtained by formal condensation of the carboxy group of L-threonine with the amino group of L-lysine.


Val-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-valine with the amino group of L-threonine.


cyclo(L-tyrosyl-L-tyrosyl)

A cyclo(tyrosyl-tyrosyl) in which both stereocentres have L-configuration. Synthesized by Mycobacterium tuberculosis.


Thr-Tyr

A dipeptide composed of L-threonine and L-tyrosine joined by a peptide linkage.


Pro-Hyp

A dipeptide composed of L-proline and L-hydroxyproline residues. It is a biomarker for bone collagen degradation.


Glu-Gln

A dipeptide obtained by formal condensation of the carboxy group of L-glutamic acid with the amino group of L-glutamine.


Phe-Gly

A dipeptide formed from L-phenylalanine and glycine residues.


ALBONOURSIN

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which the two hydrogen at position 3 and those at position 6 are replaced by benzylidene and isobutylidene groups (the 3Z,6Z-geoisomer).


Major species at pH 7.3.


Arg-Met

A dipeptide formed from L-arginine and L-methionine residues.


Ser-Gln

A dipeptide formed from L-serine and L-glutamine residues.


Met-Arg

A dipeptide formed from L-methionine and L-arginine residues.


Pro-Ser

A dipeptide formed from L-proline and L-serine residues.


Lys-Glu

A dipeptide formed from L-lysine and L-glutamic acid residues.


Thr-Leu

A dipeptide formed from L-threonine and L-leucine residues.


Glu-Ile

A dipeptide obtained by formal condensation of the carboxy group of L-glutamic acid with the amino group of L-isoleucine.


L-Orn-D-Glu

A dipeptide obtained by formal condensation of the carboxy group of L-ornithine with the amino group of D-glutamic acid. It is a constituent of bacterial peptidoglycan type A4beta.


Trp-Trp

A dipeptide formed from two L-tryptophan residues.


Met-Gln

A dipeptide formed from L-methionine and L-glutamine residues.


Trp-Asn

A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-asparagine.


cyclo(dehydrophenylalanyl-L-leucyl)

A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which two hydrogen at position 3 and one hydrogen at position 6 are replaced by benzylidene and isobutyl groups respectively.


Thr-Ala

A dipeptide formed from L-threonine and L-alanine residues.


Tyr-Pro

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-proline.


Val-Lys

A dipeptide formed from L-valine and L-lysine residues.


PROTUBONINE B

An acetate ester obtained by the formal condensation of the hydroxy group of the fungal metabolite  protubonine A with acetic acid. It has been isolated from Aspergillus species.


Lys-Tyr

A dipeptide formed from L-lysine and L-tyrosine residues.


Tyr-Ala

A dipeptide formed from L-tyrosine and L-alanine residues.


L-arginyl-L-glutamic acid

A dipeptide comprising L-arginine with a L-glutamic acid residue attached to the N(1) nitrogen.


Ile-Ser

A dipeptide formed from L-isoleucine and L-serine residues.


A dipeptide formed by formal condensation of the carboxy group of (3R)-3-methyl-D-ornithine with the side-chain amino group of L-lysine.


NBD-N(Me)-DbetaA-OH

A dipeptide comprising in sequence alpha-aspartyl and beta-alanyl residues, to the nitrogen of the aspartyl residue of which are linked both a methyl group and a 7-nitro-2,1,3-benzoxadiazol-4-yl moiety.


Ile-Thr

A dipeptide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of L-threonine.


belongs to the class of organic compounds known as dipeptides. TMAP was previously an unknown potential plasma biomarker for glomerular filtration rate (GFR) but its structure has since been elucidated (PMID: 28706470 ). TMAP has also been identified as a potential plasma biomarker of reduced kidney function in early chronic kidney disease (CKD), end stage renal disease (ESRD), and hemodialytic clearance (PMID: 31048706 )


Thr-Gln

A dipeptide formed from L-threonine and L-glutamine residues.


L-prolylglycine

A dipeptide consisting of glycine having an L-prolyl group attached to its alpha-amino nitrogen.


Met-Thr

A dipeptide formed from L-methionine and L-threonine residues.


Phe-Ala

A dipeptide formed from L-phenylalanine and L-alanine residues.


gamma-glutamyl-Se-methylselenocysteine

A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of Se-methylselenocysteine.


Asn-Trp

A dipeptide obtained by formal condensation of the carboxy group of  L-asparagine with the amino group of L-tryptophan.


Dnp-Pro-Gln

A dipeptide consisting of L-proline substituted on nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.


Cys(IAN)-Gly

An S-conjugate in which the mercapto hydrogen of L-cysteinylglycine has been replaced by a cyano(indol-3-yl)methyl group.


alpha-Asp-Ile

A dipeptide that is the N-(L-alpha-aspartyl) derivative of L-isoleucine.


Gly-Tyr

A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage.


7-dimethylallyl neoechinulin B anion

Major microspecies at pH 7.3.


Val-Ile

A dipeptide formed from L-valine and L-isoleucine residues.


Tyr-Asn

A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-asparagine.


Tyr-Gly

A dipeptide formed from L-tyrosine and glycine residues.


Tyr-Val

A dipeptide formed from L-tyrosine and L-valine residues.


Asp-Gly

A dipeptide composed of L-aspartic acid and glycine joined by a peptide linkage.


Gly-Asn

A dipeptide formed from glycine and L-asparagine residues.


glycylglycine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycylglycine with the amino group of 2-naphthylamine.


A dipeptide amide obtained by formal condensation of the carboxy group of N-benzoyl-L-valylglycine with the amino group of 4-methoxy-2-naphthylamine.


Ile-Ile

A dipeptide formed from two L-isoleucine residues.


Pro-Pro

A dipeptide formed from two L-proline residues.


Val-Asn

A dipeptide formed from L-valine and L-asparagine residues.


WLL-vs

A dipeptide that is L-tryptophyl-L-leucinamide in which the N-terminal amino group has been converted to the corresponding (morpholin-4-yl)acetamide and in which one of the hydrogens attached to the nitrogen of the C-terminal amide has been replaced by a (1E)-5-methyl-1-(methylsulfonyl)hex-1-en-3-yl group. It is a selective proteasome inhibitor.


A dipeptide comprising tyrosine with a tyrosyl residue attached to the alpha-nitrogen and with each tyrosine residue being substituted at the 3- and 5-positions by iodine.


Val-Glu

A dipeptide formed from L-valine and L-glutamic acid residues.


trandolaprilat

A heterobicyclic compound that is trandolapril in which the ethyl ester group has been hydrolysed to the corresponding acid group. It is the active metabolite of the prodrug trandolapril.


alanyl glutamine

A dipeptide formed from L-alanyl and L-glutamine residues.


Glu-Asp

A dipeptide composed of L-glutamic acid and L-aspartic acid joined by a peptide linkage.


Lys-Ser

A dipeptide formed from L-lysine and L-serine residues.


A dipeptide that is cysteinylglycine in which the thiol hydrogen has been replaced by a 4-hydroxy-1-oxononan-3-yl group.


Ser-Met

A dipeptide formed from L-serine and L-methionine residues.


Pro-Cys

A dipeptide obtained by formal condensation of the carboxy group of L-proline acid with the amino group of L-cysteine.


Asp-Glu

A dipeptide formed from L-alpha-aspartyl and L-glutamic acid residues.


Phe-Ile

A dipeptide formed from L-phenylalanine and L-isoleucine residues.


Pro-Tyr

A dipeptide formed from L-proline and L-tyrosine residues.


Asn-Leu

A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-leucine.


6-hydroxytryprostatin B

A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and hydroxy groups respectively.


OGLUFANIDE

A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage.


Ile-Arg

A dipeptide formed from L-isoleucine and L-arginine residues.


A dipeptide that is N-[(2S)-2-aminobutanoyl]glycine in which the terminal amino group has been acylated by formal condensation of the 5-carboxy group of 2-oxopentanedioic acid.


Asn-Arg

A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-arginine.


Phe-Phe

A dipeptide formed from two L-phenylalanine residues.


PROTUBONINE A

An organic heterotetracyclic compound that is 6,10b,11,11a-tetrahydro-H-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-,4(3H,5aH)-dione substituted by an acetyl group at position 6, a hydroxy group at position 10b and a 2-methylpropyl group at position 3. It has been isolated from  in Aspergillus species.


alpha-Asp-Leu

A dipeptide that is the N-(L-alpha-aspartyl) derivative of L-leucine.


name: L-Alaninamide, glycyl-N-(2-mercaptoethyl)-, 2,2'-disulfide bis(trifluoroacetate)


Asn-Asn

A dipeptide formed from two L-asparagine units.


bentiromide

The dipeptide obtained by condensation of N-benzoyl-L-tyrosine with 4-aminobenzoic acid. Used as a noninvasive screening test for exocrine pancreatic insufficiency and to monitor the adequacy of supplemental pancreatic therapy, it is given by mouth: the amount of 4-aminobenzoic acid and its metabolites excreted in the urine is taken as a measure of the chymotrypsin-secreting activity of the pancreas.


mycocyclosin

An organic heterotetracyclic compound obtained via intramolecular oxidative aromatic coupling of cyclo(L-tyrosyl-L-tyrosyl).


An N-(2-naphthyl)carboxamide obtained by formal condensation of the C-terminal carboxy group of L-glutamyl-L-glutamic acid with the amino group of 2-naphthylamine.


gamma-Glu-Ala

A gamma-glutamylalanine obtained by formal condensation of the gamma-carboxy group of L-glutamic acid with the amino group of L-alanine.


Leu-Ile

A dipeptide formed from L-leucine and L-isoleucine residues.


Arg-Ala

A dipeptide formed from L-arginyl and L-alanine residues.


Gln-Val

A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of L-valine.


A dipeptide consisting of N-butyl-L-serinamide having an (R)-2-amino-2-(4-hydroxyphenyl)acetyl residue attached to its alpha-amino nitrogen. A synthetic determinant of cefadroxil, it is a promising tool for determining in vitro cross-reactivity to cefadroxil in amoxicillin-allergic patients.


Ac-D-His-Pro

A dipeptide that is the N-(N(alpha)-acetyl-D-histidyl) derivative of L-proline.


Gly-Pro

A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.


L-leucylglycine 2-naphthylamide

An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of L-leucylglycine with the amino group of 2-naphthylamine.


Phe-Met

A dipeptide formed from L-phenylalanine and L-methionine residues.


Ser-Ile

A dipeptide obtained by formal condensation of the carboxy group of L-serine with the amino group of L-isoleucine.


Val-FMDP

A  dipeptide composed of 3-{[(2E)-4-methoxy-4-oxobut-2-enoyl]amino}alanine and L-valine joined by peptide linkages.


LEU-ALA

A dipeptide composed of L-leucine and L-alanine joined by a peptide linkage.


Pro-Asn

A dipeptide formed from L-proline and L-asparagine residues.


Cys-Cys

A dipeptide formed from two L-cysteine residues.


His-Ala

A dipeptide formed from L-histidine and L-alanine residues.


A non-proteinogenic dipeptide anion formed from L-glutamate and L-propargylglycine residues. Major species at pH 7.3.


Asn-Tyr

A dipeptide composed of L-asparagine and L-tyrosine joined by a peptide linkage.


Tyr-Glu

A dipeptide formed from L-tyrosine and L-glutamic acid residues.


Leu-Val

A dipeptide formed L-leucine and L-valine residues.


D-Ala-Gly

A dipeptide formed from D-alanine and glycine residues.


Val-His

A dipeptide formed from L-valine and L-histidine residues.


enalaprilat

Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.


Leu-Asp

A dipeptide formed from L-leucine and L-aspartic acid residues.


gamma-Glu-Val

A glutamyl-L-amino acid that is the N-(L-gamma-glutamyl) derivative of L-leucine.